Regeneron, Ocular Ink Deal for New Eylea Formulation

Oct 14, 2016

Ocular Therapeutix and Regeneron Pharmaceuticals have announced a $315 million deal to develop a sustained-release form of Regeneron’s Eylea.

Eylea generated $3.24 billion in sales in 2015 and now Regeneron is looking to develop a formulation that will cut down on injection frequency in patients suffering from wet age-related macular degeneration.

Under the terms of the deal, Bedford, MA-based Ocular is responsible for the costs of developing the formulation through Phase 1, and Regeneron will take over development, FDA filing, and commercialization, if it’s approved.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments